BioSpace News Archive

Drug Development

Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain

Linzagolix overall efficacy and safety maintained or improved at week 24

October 1, 2018
·
8 min read
Business

Nobel Prize in Medicine Awarded to Checkpoint Inhibitor Pioneers

Harnessing the body’s own immune system to fight cancer has been one of the key focuses of drugmakers over the past several years. This year, the Nobel committee recognized two research pioneers for their trailblazing efforts in this field.

October 1, 2018
·
2 min read
·
Alex Keown
Talk to Me! How to Work With That Colleague Who Is a Non-Communicator

Your earning potential and career growth can be stunted if you don’t know how to handle a co-worker (or boss) who doesn’t communicate well. Here are three ways to improve your relationship with a colleague who is a non-communicator.

October 1, 2018
·
4 min read
·
Porschia Parker
UgenTec to extend its software portfolio with FastTyper, a platform used for high-throughput SNP genotyping by end-point PCR

UgenTec today announced a new end-point PCR analysis software called FastTyper.

October 1, 2018
·
2 min read
Business

Dragonfly and Merck Strike $695 Million Deal for Solid Tumors

Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck. Merck will license exclusive rights to Dragonfly’s TriNKET technology platform for a number of solid-tumor programs, the company announced today.

October 1, 2018
·
2 min read
·
Alex Keown
Business

Pfizer Announces Ian Read’s Replacement and Succession Plan

Pfizer announced its succession plan for when Ian Read steps down as chief executive officer on January 1, 2019. The new chief executive officer will be Albert Bourla, who is currently the company’s chief operating officer.

October 1, 2018
·
2 min read
·
Mark Terry
Business

Arix Bioscience Leads $58 Million Series A into VelosBio, Taking 11.2% Stake

VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.

October 1, 2018
·
2 min read
·
Mark Terry
Deals

Israel-Based Gamida Cell Files for $69 Million IPO

Gamida Cell Ltd. filed for a $69 million initial public offering for the Nasdaq exchange, according to a filing submitted last week to the U.S. Securities and Exchange Commission, Israel’s Calcalist first reported last week.

October 1, 2018
·
2 min read
·
Alex Keown
Policy

One Company Owns Almost Half of Marine Gene Sequence Patents: What It Could Mean for Drug Discovery

German chemical company BASF, the world’s largest chemical producer, has registered 47 percent of patented marine organism gene sequences, according to a study published in Science Advances in June.

October 1, 2018
·
4 min read
·
Chelsea Weidman Burke
Deals

Updated: BioSpace’s List of October 2018 Life Sciences IPOs

A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.

October 1, 2018
·
2 min read
·
Editorial Staff